发明名称 ANTIHUMAN CCR7 ANTIBODIES, HYBRIDOMA, NUCLEIC ACID, VECTOR, CELL, MEDICINAL COMPOSITION, AND ANTIBODY-IMMOBILIZED CARRIER
摘要 An object of the present invention is to provide a novel anti-human CCR7 antibody useful as a therapeutic agent for tissue fibrosis or cancer, and a pharmaceutical composition containing the anti-human CCR7 antibody, and the like. An anti-human CCR7 antibody specifically binding to an extracellular domain of human CCR7, having a heavy chain CDR3 containing an amino acid sequence represented by SEQ ID NO: 7, SEQ ID NO: 17, SEQ ID NO: 27, SEQ ID NO: 37, SEQ ID NO: 47, SEQ ID NO: 57, SEQ ID NO: 67, or SEQ ID NO: 77 is provided. Also provided is an anti-human CCR7 antibody having heavy chain CDRs 1-3 and light chain CDRs 1-3 containing amino acid sequences represented by SEQ ID NOs: 5-10, 15-20, 25-30, 35-40, 45-50, 55-60, 65-70, or 75-80. Preferably, the antibody has an activity of interfering with a CCR7-dependent intracellular signal transduction mechanism caused by CCR7 ligand stimulation. The anti-human CCR7 antibody of the present invention may be used as an active ingredient of a therapeutic agent for tissue fibrosis or cancer.
申请公布号 EP2623592(A4) 申请公布日期 2014.05.14
申请号 EP20110829086 申请日期 2011.09.27
申请人 SEKISUI CHEMICAL CO., LTD.;NB HEALTH LABORATORY CO. LTD. 发明人 NISHIGUCHI NAOKI;HIRAYAMA, AKIYOSHI;FURUTANI MASAHIRO;SHIMIZU TATSUO;TAKAYAMA KIYOSHI;SHIMIZU TOMOKO;SUZUKI KAZUYA
分类号 C12N15/09;A61K31/713;A61K39/395;A61P1/04;A61P1/16;A61P3/10;A61P9/04;A61P9/10;A61P9/12;A61P11/00;A61P11/06;A61P13/12;A61P17/00;A61P17/02;A61P17/06;A61P19/02;A61P29/00;A61P35/00;A61P35/02;A61P35/04;A61P43/00 主分类号 C12N15/09
代理机构 代理人
主权项
地址